AI Article Synopsis
- Ovarian cancer has a high mortality rate partly due to drug-resistant disease, highlighting the need for new chemotherapeutics like histone deacetylase inhibitors (HDAIs).
- In experiments, combining HDAIs with paclitaxel (PTX) effectively induced cell death in ovarian cancer cells, matching the effectiveness of continuous PTX and outperforming continuous HDAI alone.
- The order of drug administration impacted the effectiveness of the treatment, but the p53 status of the cells did not affect the outcomes, indicating HDAIs could be beneficial as an additional therapy for ovarian cancer.
Article Abstract
Background: Recurrence of drug-resistant disease contributes to the high mortality of ovarian cancer patients, which necessitates the identification of additional chemotherapeutic drugs. Histone deacetylase inhibitors (HDAIs) induce apoptosis in a number of malignant cell types and may represent a new class of drugs clinically relevant in the treatment of ovarian cancer.
Materials And Methods: Ovarian cancer cells were treated with various combinations of a HDAI and paclitaxel (PTX). Cell death was measured using annexin V/propidium iodide exclusion.
Results: The PTX/HDAI drug combination was as efficient in inducing cell death as continuous PTX treatment and superior to continuous HDAI treatment. Reversing the sequence of drug exposure reduced the cytotoxic efficacy of the drug combination. The p53 status of the cell lines did not alter the cytotoxic efficacy of the treatment protocols.
Conclusion: These results suggest that HDAIs possess possible clinical applications as an adjuvant therapy in the treatment of ovarian cancer.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!